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Abstract The endocannabinoid (eCB) system has recently
been implicated in both the pathogenesis of depression and
the action of antidepressants. Here, we investigated the
effect of acutely or chronically administering antidepres-
sants [imipramine (IMI) (15 mg/kg), escitalopram (ESC)
(10 mg/kg), and tianeptine (10 mg/kg)] on the levels of both
eCBs [anandamide (AEA) and 2-arachidonoylglycerol
(2-AG)] and N-acylethanolamines (NAEs) [palmitoyle-
thanolamide (PEA) and oleoylethanolamide (OEA)] in
various rat brain regions. We also examined the ability of the
acute and chronic administration of N-acetylcysteine (NAC)
(a mucolytic drug; 100 mg/kg) or URB597 (a fatty acid
amide hydrolase inhibitor; 0.3 mg/kg), which have both
elicited antidepressant activity in preclinical studies, to
affect eCB and NAE levels. Next, we determined whether
the observed effects are stable 10 days after the chronic
administration of these drugs was halted. We report that the
chronic administration of all investigated drugs increased
AEA levels in the hippocampus and also increased both
AEA and 2-AG levels in the dorsal striatum. NAE levels
in limbic regions also increased after treatment with IMI
(PEA/OEA), ESC (PEA), and NAC (PEA/OEA). Removing
chronic ESC treatment for 10 days affected eCB and NAE
levels in the frontal cortex, hippocampus, dorsal striatum,
and cerebellum, while a similar tianeptine-free period
enhanced accumbal NAE levels. All other drugs maintained
their effects after the 10-day washout period. Therefore,
the eCB system appears to play a significant role in the
mechanism of action of clinically effective and potential
antidepressants and may serve as a target for drug design and
discovery.
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Abbreviations
AEA Anandamide
2-AG 2-Arachidonoylglycerol
eCBs Endocannabinoids
ESC Escitalopram
IMI Imipramine
LC–MS/MS Liquid chromatography tandem mass
spectrometry
NAC N-Acetylcysteine
NAEs N-Acylethanolamines
OEA Oleoylethanolamide
PEA Palmitoylethanolamide
TIA Tianeptine
Introduction
Depression is the leading cause of disability and the 4th
highest contributor to the global disease burden in the
twenty-first century. Despite the existence of several pre-
clinical and clinical studies, the pathophysiology of this
brain disorder remains unclear. In addition, currently pre-
scribed antidepressants are often therapeutically inadequate
in many patients. Although the role of stress, infectious
agents, and genetic influence in depression has been well
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documented, the cause(s) of depression have not yet been
completely elucidated. Previous attempts to identify the
pathomechanism of depression have relied on the mecha-
nism of action of antidepressants; however, the psycho-
pharmacology of these drugs is also poorly understood. In
the clinic, several antidepressants with different mecha-
nisms of action are commonly used, which suggests that
the specific interaction of the drug with its target is not
responsible for its therapeutic efficacy; instead, there is
likely a secondary effect that is important. The endocan-
nabinoid (eCB) system is involved in modulating emo-
tional responses, memory and learning, and several
previous studies have implicated this system in the patho-
genesis of depression. Some possible mechanisms of action
include relocalizing CB1 receptors (among the limbic
system, the reward system and midbrain monoaminergic
nuclei), modulating monoaminergic transmission (through
noradrenaline (NA), serotonin (5-HT), dopamine (DA), c-
aminobutyric acid (GABA), and glutamate), inhibiting the
activation of the stress axis and promoting neuroplasticity
in the brain (Micale et al. 2013). Eliminating CB1 receptors
in mice results in a phenotype that closely resembles the
symptoms of severe, typical depression, while blocking
CB1 receptor induces a melancholic depression (Sanchis-
Segura et al. 2004; Aso et al. 2008; Steiner et al. 2008;
Mikics et al. 2009). In human clinical trials, patients who
received the CB1 receptor antagonist rimonabant
(SR141716A) to treat obesity also experienced symptoms
of anxiety and depression (Christensen et al. 2007).
Several studies have also suggested that facilitating the
eCB system by inhibiting fatty acid amide hydrolase
(FAAH) URB597 promotes a positive mood and possibly
exerts antidepressant-like behavioral responses in rodents
(Rutkowska and Jachimczuk 2004; Gobbi et al. 2005; Hill
and Gorzalka 2005; Jiang et al. 2005; Bambico et al. 2007;
Naidu et al. 2007; Adamczyk et al. 2008; Realini et al.
2011). Other recent studies have implicated the eCB sys-
tem in behavioral changes following antidepressant drug
treatment (Hill et al. 2006, 2008b, c; Rodriguez-Gaztelu-
mendi et al. 2009; Mato et al. 2010).
The goals of this study were twofold. First, we set out to
determine the effect of chronic or acute administration of
antidepressant drugs on biomarkers in the eCB system by
analyzing eCB and eCB-like molecules in the rat brain
either 24 h later or after a 10-day drug-free period fol-
lowing chronic drug administration. Second, we wanted to
characterize the common adaptive changes that follow the
administration of these antidepressant drugs. We first
focused on determining whether the acute or chronic
administration of antidepressants affected the levels of
eCBs [anandamide (AEA) and 2-arachidonoylglycerol
(2-AG)] or N-acylethanolamines (NAEs) [oleoylethanola-
mide (OEA) and palmitoylethanolamide (PEA)]. A
subsequent 10-day drug-free period was implemented to
determine whether the effects of these drugs on eCB/NAE
levels are maintained after the treatment is discontinued.
We selected those antidepressants that are most commonly
prescribed by doctors, including imipramine (IMI, a NA
and 5-HT reuptake inhibitor), escitalopram (ESC, a selec-
tive 5-HT reuptake inhibitor), and tianeptine (TIA, a
selective 5-HT reuptake enhancer) along with drugs in
which antidepressant activity has been more recently
demonstrated in preclinical research, including URB597 (a
FAAH inhibitor) (Gobbi et al. 2005; Adamczyk et al. 2008)
and N-acetylcysteine (NAC, a mucolytic drug and a puta-
tive precursor of the primary tissue antioxidant glutathione)
(Ferreira et al. 2008; Smaga et al. 2012). Previous studies
have demonstrated that URB597, a selective inhibitor of
the enzyme (FAAH) that catalyzes the intracellular
hydrolysis of eCBs, can exert potent antidepressant-like
effects in the mouse tail-suspension test (TST) and the rat
forced-swim test (FST) that are comparable to those seen
after IMI treatment (Gobbi et al. 2005; Adamczyk et al.
2008). The chronic administration of NAC was also found
to exert an antidepressant-like effect in a dose-dependent
manner in rats, which was demonstrated by the reduction in
immobility time in the FST (Ferreira et al. 2008). In our
study, bulbectomized rats exhibited a similar reduction,
which was associated with the reinforcement of brain
antioxidant defense mechanisms (Smaga et al. 2012).
Materials and Methods
Animals
The experiments were performed on male Wistar rats
(250–300 g). The animals were kept on normal day–night
cycle, at 22 ± 2 C with access to food and water ad libi-
tum. All experiments were carried out in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and with approval of the Bio-
ethics Commission as compliant with the Polish Law (21
August 1997). N = 8 rats/group.
Drugs
The following drugs were used: imipramine hydrochloride
(IMI; Sigma Aldrich, USA), escitalopram oxalate (ESC;
Lundbeck, Denmark), tianeptine sodium (TIA; Anpharm,
Poland), N-acetylcysteine (NAC; Sigma Aldrich, USA) and
cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester
(URB597, Sigma Aldrich, USA). IMI, ESC, TIA, and NAC
were dissolved in sterile 0.9 % NaCl (pH of a NAC and
ESC solution has been neutralized with 10 % NaOH
solution). URB597 was dissolved in 2–3 drops of ethanol
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and diluted as required in a 1 % aqueous solution Tween
80. Drugs were given once per day between 9:00 and 12:00
ip acutely or chronically (14 days), in addition, single dose
of URB597 (0.3 mg/kg) was injected 2 h before decapita-
tion of rats (N = 6 rats) to control the method of eCBs/
NAEs determination (Table 1). The injection volume was
1 ml/kg of body weight. The doses for drugs were chosen
based on effective doses used in our previous behavioral
observations: NAC (100 mg/kg) (Smaga et al. 2012) and
URB597 (Adamczyk et al. 2008) as well as in other liter-
ature findings on IMI (15 mg/kg) (Tokita et al. 2012), ESC
(10 mg/kg) (Reed et al. 2009), and TIA (10 mg/kg)
(Whitton et al. 1991).
Brain Structures Isolation
2 h (single administration of URB597), 24 h (acute and
chronic administration), or 10 days (washout period after
14-day chronic administration) after last administration rats
were sacrificed through decapitation. Selected brain struc-
tures (i.e., the prefrontal cortex, frontal cortex, hippocam-
pus, dorsal striatum, nucleus accumbens, and cerebellum)
were isolated, immediately frozen on dry ice and stored at
-80 C. Tissues were dissected out according to The Rat
Brain Atlas (Paxinos and Watson 1998).
LC–MS/MS Analysis
Reagents
All chemical solvents and standards were of analytical
grade. Standards of AEA, 2-AG, OEA, and PEA were
obtained from Tocris (Bristol, United Kingdom), AEA-d4,
2-AG-d5, OEA-d4, and PEA-d4 from Cayman Chemical
(USA), acetonitrile and chloroform from Merck (Darms-
tadt, Germany), methanol and formic acid from POCh
(Katowice, Poland). Standards stock solutions were pre-
pared in ethanol, except from 2-AG and 2-AG-d5 which
were prepared in acetonitrile. All stock solutions were
stored at -80 C. Further dilutions were carried out
appropriately in acetonitrile.
Lipid Extraction from Brain Tissue
The brain tissues were weighted and subjected to eCB and
NAE extraction. Extraction was carried out by the modified
methods of isolation of lipid compounds developed by
Folch et al. (1957). Tissues were homogenized using son-
ificator (UP50H, Hielscher) in the ice-cold mixture of
methanol and chloroform (1:2; v/v) in proportion 10 mg of
wet tissue to 150 ll of solvent to quench any possible
enzymatic reaction that may interfere with the analysis.
Next, 150 ll of homogenate were mixed with 2 ll of
internal standard (AEA-d4, concentration 10 lg/ml; 2-AG-
d5, concentration 100 lg/ml; PEA-d4, OEA-d4, concen-
tration 5 lg/ml), 250 ll of formic acid (pH 3.0; 0.2 M) and
1,500 ll of extraction mixture (methanol:chloroform; 1:2,
v/v). The internal standard indicates analyte loss during
sample work-up. Afterward, samples were vortexed for
30 s and centrifuged for 10 min at 2,000 rpm. Organic
phases were collected and dried under a stream of nitrogen
at 40 C. The residue was dissolved in 40 ll of acetonitrile,
and 10 ll of the reconstituted extract was injected into the
LC–MS/MS system for quantitative analysis.
LC–MS/MS Conditions
LC was performed using an Agilent 1100 (Agilent Tech-
nologies, Waldbronn, Germany) LC system. Chromato-
graphic separation was carried out with a Thermo Scientific
BDS HYPERSIL C18 column (100 9 3 mm I.D., 3 lm
particle size). The advance column, with precolumn
(10 9 3 mm I.D., 3 lm particle size) set at 40 C with a
mobile phase flow rate of 0.3 ml/min. Gradient elution
mobile phases were consisted of formic acid (0.02 M) in
water (solvent A) and formic acid (0.02 M) in acetonitrile
(solvent B). The gradient began initially at 0 % A during
1 min, increasing linearly to 90 % at 2 min, this was
maintained for 2 min and then decreasing to 0 % at 6 min.
Table 1 Experimental protocol
1–13 days 14 day
Single administration
Vehicle IMI Decapitation—at 24 h
after last injectionVehicle ESC
Vehicle Tianeptine
Vehicle N-Acetylcysteine
Vehicle URB597
– URB597 Decapitation—at 2 h
after injection
Chronic administration
IMI IMI
ESC ESC Decapitation—at 24 h
after last injectionTianeptine Tianeptine
N-Acetylcysteine N-Acetylcysteine
URB597 URB597
Chronic administration with 10-day washout period
IMI IMI Decapitation—at 10 days
after last injectionESC ESC
Tianeptine Tianeptine
N-Acetylcysteine N-Acetylcysteine
URB597 URB597
For each drug the control group of rats was generated by single or
chronic administration of corresponding vehicle. N = 6–8 rats/group
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Finally, last 4 min of analysis was kept at 100 % B.
Sample temperature was maintained at 4 C in the auto-
sampler prior to analysis. A sample volume of 10 ll was
injected into the analytical column for compound analysis.
MS/MS analyses were accomplished on an Applied
Biosystems MDS Sciex (Concord, ON, Canada) API 2000
triple quadruple mass spectrometer equipped with an
electrospray ionization (ESI) interface. ESI ionization was
performed in the positive ionization mode. A standard
polypropylene glycols solution (PPG standard) was used
for instrument tuning and mass calibration at unit mass
resolution according to the Applied Biosystems manual.
The mass spectrometer was operated with a dwell time of
200 ms. To find the optimal parameters of ion path and ion
source of the studied compound, the quantitative optimi-
zation was done by direct infusion of standards using a
Hamilton syringe pump (Hamilton, Reno, NV, USA).
Multiple reaction monitoring (MRM) mode of the domi-
nant product ion for each eCB/NAE was realized using the
optimal conditions. The ion source parameters were as
follows: ion spray voltage (IS): 5,500 V; nebulizer gas (gas
1): 30 psi; turbo gas (gas 2): 10 psi; temperature of the
heated nebulizer (TEM): 400 C; curtain gas (CUR): 25
psi. Comparison of pair ion (precursor and product ion m/
z values) and LC retention times with standards served to
confirm the identification of eCB/NAE in the samples
investigated. Ion pair was 348/62 for AEA, 379/287 for
2-AG, 326/62 for OEA, 300/62 for PEA, 352/66 for AEA-
d4, 384/292 for 2-AG-d5, 330/66 for OEA-d4, and 304/66
for PEA-d4. Data acquisition and processing were accom-
plished using the Applied Biosystems Analyst version 1.4.2
software.
Calibration Curve and Quantification
eCB and NAE concentrations in samples were calculated
using the calibration curve that was prepared on the same
day and analyzed in the same analytical run. Calibration
curves were constructed after the analysis of samples of
brain tissues collected from naive rats. The homogenates
were spiked with AEA, OEA, and PEA to the following
concentration: blank, 0.1, 1, 10, 25, 50, 100 ng/g. Solutions
used for 2-AG were: blank, 0.4, 1, 5, 10, 25, 50 lg/g. AEA-
d4, 2-AG-d5, PEA-d4, OEA-d4 were used as the internal
standard. These samples were analyzed according to the
procedure described for sample preparation (‘‘Lipid
extraction from brain tissue’’ section).
Statistical Analyses
All data were expressed as means (±SEM). Statistical
analyses were performed with either Student’s t test or one-
way analysis of variance (ANOVA), followed by Dunnett’s
test to analyze differences between group means. p \ 0.05
was considered statistically significant.
Results
Concentration of eCB in Rat Brain Structures
AEA
IMI (15 mg/kg) treatment caused the changes in the AEA
levels in the hippocampus (F(2,21) = 34.29; p \ 0.0001)
and dorsal striatum (F(2,21) = 21.21; p \ 0.0001). Post
hoc analyses revealed the significant increase of AEA in
the hippocampus (p \ 0.001) after acute administration of
IMI. After chronic administration of IMI, an increase of
AEA levels was reported in the hippocampus (p \ 0.01)
and dorsal striatum (p \ 0.001) (Fig. 1). A 10-day washout
period after chronic treatment of IMI restored the levels of
AEA to the levels of vehicle-treated animals in all struc-
tures (Fig. 2).
After ESC (10 mg/kg) treatment, the changes in the
AEA levels were seen in the hippocampus (F(2,21) =
0.3888; p = 0.0366) and dorsal striatum (F(2,21) = 7.240;
p = 0.0041). After chronic administration of ESC, an
increase of AEA concentration was noted in the hippo-
campus (p \ 0.05) and dorsal striatum (p \ 0.05), while
acute administration of ESC did not change the basal levels
of AEA (Fig. 1). 10 days after the last administration, an
increase of AEA levels was seen only in the hippocampus
(t = 2.407, df = 14, p \ 0.05) (Fig. 2).
TIA (10 mg/kg) evoked changes in the AEA concen-
tration in the hippocampus (F(2,21) = 4.036; p = 0.0329)
and dorsal striatum (F(2,21) = 5.703; p = 0.0105). Acute
administration of TIA did not change AEA levels, whereas
repeated daily injections of TIA resulted in an increase in
the hippocampus (p \ 0.05) and dorsal striatum (p \ 0.01)
(Fig. 1). A 10-day washout period after chronic treatment
of TIA restored the levels of AEA to the levels of vehicle-
treated animals in all structures (Fig. 2).
NAC (100 mg/kg) treatment resulted in changes of AEA
levels in the frontal cortex (F(2,21) = 5.209; p = 0.0146),
hippocampus (F(2,21) = 12.91; p = 0.0002) and dorsal
striatum (F(2,21) = 37.10; p \ 0.0001). Acute adminis-
tration of NAC increased the AEA levels in the dorsal
striatum (p \ 0.001), while chronic administration of NAC
increased the AEA levels in the frontal cortex (p \ 0.05),
hippocampus (p \ 0.001), and dorsal striatum (p \ 0.01)
(Fig. 1). A 10-day washout period after chronic treatment
of NAC restored the levels of AEA to the levels of vehicle-
treated animals in all structures (Fig. 2).
Administration of URB597 (0.3 mg/kg) caused the
changes in the AEA levels in the hippocampus
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(F(2,21) = 8.311; p = 0.0022), dorsal striatum (F(2,21) =
5.787; p = 0.01) and cerebellum (F(2,21) = 17.03;
p \ 0.0001). Chronic administration of URB597 evoked an
increase of AEA levels in the hippocampus (p \ 0.05),
dorsal striatum (p \ 0.05), and cerebellum (p \ 0.001)
(Fig. 1). Neither acute administration nor 10-day drug-free
period changed the AEA levels in the examined rat brain
structures (Fig. 2).
For comparison, the levels of AEA measured 2 h after
single administration of URB597 increased in the hippo-
campus (t = 4.342, df = 10, p \ 0.01), dorsal striatum
(t = 3.172, df = 10, p \ 0.01), and cerebellum (t =
4.515, df = 10, p \ 0.01) (Table 2).
2-AG
IMI (15 mg/kg) treatment resulted in a change in the 2-AG
levels in the frontal cortex (F(2,21) = 6.385; p = 0.0068),
dorsal striatum (F(2,21) = 11.37; p = 0.0005), and cere-
bellum (F(2,21) = 7.035; p = 0.0046). The 2-AG levels
either increased in the frontal cortex (p \ 0.05) or
decreased in the cerebellum (p \ 0.05) after acute
administration of IMI. IMI administered chronically
evoked an increase of 2-AG levels in the frontal cortex
(p \ 0.01) and dorsal striatum (p \ 0.001), while in the
cerebellum (p \ 0.01) reduced 2-AG levels were reported
(Fig. 3). A 10-day washout period after chronic treatment
of IMI restored the levels of 2-AG to the levels of vehicle-
treated animals in all structures (Fig. 4).
Administration of ESC (10 mg/kg) resulted in potent
changes in the 2-AG concentration in the prefrontal cortex
(F(2,21) = 6.169; p = 0.0078), frontal cortex (F(2,21) =
8.656; p = 0.0018), hippocampus (F(2,21) = 3.447;
p = 0.0508), dorsal striatum (F(2,21) = 3.848; p =
0.0377), and cerebellum (F(2,21) = 3.843; p = 0.0378).
ESC administered acutely decreased the 2-AG levels in the
frontal cortex (p \ 0.05). Chronic administration of ESC
caused a reduction in the 2-AG levels in the prefrontal
cortex (p \ 0.01), frontal cortex (p \ 0.01), and cerebel-
lum (p \ 0.05), while an increase of 2-AG concentration
was seen in the hippocampus (p \ 0.05) and dorsal stria-
tum (p \ 0.05) (Fig. 3). After 10-day drug-free period an
increase of 2-AG levels was noted only in the hippocampus
(t = 2.272, df = 14, p \ 0.05) and dorsal striatum
(t = 3.062, df = 14, p \ 0.01) (Fig. 4).
Fig. 1 AEA levels in rat brain structures following acute and chronic
drug/compound administration. AEA Anandamide, IMI(15) imipra-
mine hydrochloride (15 mg/kg), ESC(10) escitalopram oxalate,
TIA(10) tianeptine sodium, NAC(100) N-acetylcysteine, URB597(0.3)
cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester, PFCTX
prefrontal cortex, FCTX frontal cortex, HIP hippocampus, DSTR
dorsal striatum, NAc nucleus accumbens, CER cerebellum. All data are
expressed as the mean ± SEM. N = 8 rats/group. *p \ 0.05;
**p \ 0.01; ***p \ 0.001 versus corresponding vehicle
194 Neurotox Res (2014) 26:190–206
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TIA (10 mg/kg) caused changes in the 2-AG levels in
the frontal cortex (F(2,21) = 6.997; p = 0.0047) and
dorsal striatum (F(2,21) = 4.073; p = 0.032). Repeated
daily injections of TIA resulted in an increase of 2-AG
levels in the frontal cortex (p \ 0.01) and dorsal striatum
(p \ 0.05), while TIA administered acutely did not change
the 2-AG levels (Fig. 3). 10-day drug-free period caused
reduction in the 2-AG levels in the frontal cortex
(t = 5.294, df = 14, p \ 0.001) (Fig. 4).
NAC (100 mg/kg) treatment evoked changes in the
prefrontal cortex (F(2,20) = 9.116; p = 0.0015), frontal
cortex (F(2,21) = 26.09; p \ 0.0001), dorsal striatum
(F(2,21) = 22.26; p\0.0001), nucleus accumbens (F(2,21) =
8.139; p = 0.0024), and cerebellum (F(2,21) = 5.187;
p = 0.0148). NAC administered acutely caused a decrease
of 2-AG levels in the prefrontal cortex (p \ 0.01) and
cerebellum (p \ 0.05). After chronic administration of
NAC a decrease of 2-AG concentration was seen in
the prefrontal cortex (p \ 0.05), nucleus accumbens
(p \ 0.01) and cerebellum (p \ 0.05) and an increase of
2-AG concentration was noted in the frontal cortex
(p \ 0.001) and dorsal striatum (p \ 0.001) (Fig. 3). A
10-day washout period after chronic treatment of NAC
restored the levels of 2-AG to the levels of vehicle-treated
animals in all structures (Fig. 4).
Administration of URB597 (0.3 mg/kg) resulted in a
change of 2-AG levels only in the dorsal striatum
(F(2,21) = 4.590; p = 0.0222). An increase of 2-AG
concentration in the dorsal striatum (p \ 0.05) was repor-
ted after acute or chronic administration of URB597
(Fig. 3). A 10-day washout period after chronic treatment
of URB597 restored the levels of 2-AG to the levels of
vehicle-treated animals in all structures (Fig. 4).
For comparison, the 2-AG levels did not change 2 h
after single administration of URB597 in any structures
examined (Table 2).
Concentration of NAE in Rat Brain Structures
PEA
IMI (15 mg/kg) treatment resulted in changes of the PEA
concentration in the prefrontal cortex (F(2,20) = 10.48;
p = 0.0008), hippocampus (F(2,21) = 19.65; p \ 0.0001),
dorsal striatum (F(2,21) = 16.98; p \ 0.0001), and cere-
bellum (F(2,21) = 6.512; p = 0.0063). After acute
Fig. 2 AEA levels in rat brain structures following chronic drug/
compound administration and 10-day washout period. AEA anandamide,
IMI(15) imipramine hydrochloride (15 mg/kg), ESC(10) escitalopram
oxalate, TIA(10) tianeptine sodium, NAC(100) N-acetylcysteine,
URB597(0.3) cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester,
PFCTX prefrontal cortex, FCTX frontal cortex, HIP hippocampus, DSTR
dorsal striatum, NAc nucleus accumbens, CER cerebellum. All data are
expressed as the mean ± SEM. N = 8 rats/group. *p \ 0.05 versus
corresponding vehicle
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administration of IMI we observed either a decrease (in the
cerebellum (p \ 0.01)) or an increase of PEA concentra-
tion (in the hippocampus (p \ 0.001)). An increase of PEA
levels was seen in the prefrontal cortex (p \ 0.05) and
dorsal striatum (p \ 0.001), and a decrease was seen in
cerebellum (p \ 0.05) after chronic administration of IMI
(Fig. 5). An increase of PEA levels was observed in the
dorsal striatum (t = 2.328, df = 14, p \ 0.05) 10 days
after the last administration of IMI (Fig. 6).
After ESC (10 mg/kg) treatment, we noted that the PEA
levels changed in the frontal cortex (F(2,21) = 18.56;
p \ 0.0001), hippocampus (F(2,21) = 12.98; p = 0.0002)
and cerebellum (F(2,21) = 35.23; p \ 0.0001). A potent
decrease of PEA levels was seen in the frontal cortex
(p \ 0.001) and cerebellum (p \ 0.001) after acute
administration of ESC. ESC administrated chronically
caused an increase of PEA levels in the hippocampus
(p \ 0.001) and a decrease of PEA levels in the frontal
cortex (p \ 0.001) and cerebellum (p \ 0.001) (Fig. 5). A
10-day washout period resulted in reduction of PEA con-
centration in the frontal cortex (t = 5.744, df = 14,
p \ 0.001) and cerebellum (t = 3.683, df = 14, p \ 0.01)
(Fig. 6).
Administration of TIA (10 mg/kg) caused changes in the
PEA levels in the prefrontal cortex (F(2,21) = 3.558;
p = 0.0477) and hippocampus (F(2,21) = 36.07; p\0.0001).
A potent decrease of PEA levels was seen in the hippocampus
(p \ 0.001) after acute administration of TIA. TIA admin-
istrated chronically caused a decrease of PEA levels in the
prefrontal cortex (p \ 0.05) and hippocampus (p \ 0.001)
(Fig. 5). A 10-day drug-free period resulted in reduction of
PEA concentration in the prefrontal cortex (t = 3.111,
df = 14, p \ 0.01) and an increase of PEA levels was
reported in the nucleus accumbens (t = 4.432, df = 14,
p \ 0.001) (Fig. 6).
NAC (100 mg/kg) caused changes in the PEA levels in
the cortical structures (prefrontal (F(2,20) = 3.954;
p = 0.0357) and frontal cortex (F(2,21) = 28.12; p \
0.0001)) and dorsal striatum (F(2,21) = 15.10; p \
0.0001). Repeated daily injections of NAC resulted in an
increase of PEA levels in the prefrontal cortex (p \ 0.05),
frontal cortex (p \ 0.001), and dorsal striatum (p \ 0.001),
while NAC administered acutely did not change the PEA
levels (Fig. 5). A 10-day washout period after chronic
treatment of NAC restored the levels of PEA to the levels
of vehicle-treated animals in all structures (Fig. 6).
Administration of URB597 (0.3 mg/kg) resulted in
changes in the PEA concentration in the prefrontal cortex
(F(2,21) = 16.21; p \ 0.0001), hippocampus (F(2,21) =
5.364, p = 0.0131), and cerebellum (F(2,21) = 3.054;
p = 0.0685). URB597 administered acutely decreased the
PEA levels in the hippocampus (p \ 0.05). Chronic
administration of URB597 caused a reduction in the PEAT
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levels in the hippocampus (p \ 0.05), while an increase of
PEA concentration was seen in the prefrontal cortex
(p \ 0.001) and cerebellum (p \ 0.05) (Fig. 5). A 10-day
washout period after chronic treatment of URB597 restored
the levels of PEA to the levels of vehicle-treated animals in
all structures (Fig. 6).
For comparison, the levels of PEA measured 2 h after
single administration of URB597 increased in the hippo-
campus (t = 3.436, df = 10, p \ 0.01), dorsal striatum
(t = 5.444, df = 10, p \ 0.001), and nucleus accumbens
(t = 7.998, df = 10, p \ 0.001) (Table 2).
OEA
After administration of IMI (15 mg/kg), we observed
changes in the OEA concentration in the hippocampus
(F(2,21) = 31.62; p \ 0.0001), dorsal striatum (F(2,21) =
28.73; p \ 0.0001), and cerebellum (F(2,21) = 4.33;
p = 0.0266). IMI administered acutely increased the OEA
levels in the hippocampus (p \ 0.001) and decreased the
OEA levels in the cerebellum (p \ 0.05). Chronic admin-
istration of IMI caused an increase of OEA concentration
in the dorsal striatum (p \ 0.001) (Fig. 7). A 10-day
washout period after chronic treatment of IMI restored the
levels of OEA to the levels of vehicle-treated animals in all
structures (Fig. 8).
ESC (10 mg/kg) caused changes in the OEA levels in
the frontal cortex (F(2,21) = 17.65; p \ 0.001) and cere-
bellum (F(2,21) = 17.25; p \ 0.0001). A decrease of basal
levels of OEA was observed in the frontal cortex
(p \ 0.001) and cerebellum (p \ 0.001) after acute and
chronic administration of ESC (Fig. 7). 10-day washout
period caused reduction in the OEA levels in the frontal
cortex (t = 4.305, df = 14, p \ 0.001) and cerebellum
(t = 2.720, df = 14, p \ 0.05) (Fig. 8).
TIA (10 mg/kg) treatment caused changes in the OEA
levels only in the prefrontal cortex (F(2,21) = 12.38;
p = 0.0003). A significant decrease was observed in the
prefrontal cortex (p \ 0.01) after chronic administration of
TIA, while TIA administered acutely did not change the
OEA levels (Fig. 7). 10-day drug-free period caused an
increase of the OEA levels in the nucleus accumbens
(t = 3.881, df = 14, p \ 0.01) (Fig. 8).
After NAC (100 mg/kg) administration we observed
changes in the OEA levels in the frontal cortex
(F(2,21) = 8.198; p = 0.0023), hippocampus (F(2,21) =
Fig. 3 2-AG levels in rat brain structures following acute and chronic
drug/compound administration. 2-AG 2-Arachidonoylglycerol,
IMI(15) imipramine hydrochloride (15 mg/kg), ESC(10) escitalopram
oxalate, TIA(10) tianeptine sodium, NAC(100) N-acetylcysteine,
URB597(0.3) cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl
ester, PFCTX prefrontal cortex, FCTX frontal cortex, HIP hippocam-
pus, DSTR dorsal striatum, NAc nucleus accumbens, CER cerebellum.
All data are expressed as the mean ± SEM. N = 8 rats/group.
*p \ 0.05; **p \ 0.01; ***p \ 0.001 versus corresponding vehicle
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4.576; p = 0.0224), dorsal striatum (F(2,21) = 27.42;
p \ 0.0001) and nucleus accumbens (F(2,20) = 25.95;
p \ 0.0001). A significant decrease of OEA concentration
was noted in the nucleus accumbens (p \ 0.01) after acute
administration of NAC. After chronic administration of
NAC the OEA levels either decreased (in the nucleus
accumbens (p \ 0.001)) or increased (in the frontal cortex
(p \ 0.05), hippocampus (p \ 0.05) and dorsal striatum
(p \ 0.001)) (Fig. 7). A 10-day washout period after
chronic treatment of NAC restored the levels of OEA to the
levels of vehicle-treated animals in all structures (Fig. 8).
URB597 (0.3 mg/kg) treatment resulted in a change of
OEA levels only in the hippocampus (F(2,21) = 6.032;
p = 0.0085). The OEA levels decreased in the hippocam-
pus after single and chronic administration of URB597
(p \ 0.01 and p \ 0.05, respectively) (Fig. 7). A 10-day
washout period after chronic treatment of URB597 restored
the levels of OEA to the levels of vehicle-treated animals
in all structures (Fig. 8).
For comparison, the levels of OEA measured 2 h after
single administration of URB597 increased in the hippo-
campus (t = 2.686, df = 10, p \ 0.05), dorsal striatum
(t = 4.740, df = 10, p \ 0.001), and nucleus accumbens
(t = 4.305, df = 10, p \ 0.01) (Table 2).
Discussion
This paper reveals the effects of both antidepressants and
drugs with antidepressant-like activity (see ‘‘Introduction’’
section) on the levels of eCBs and NAEs in ex vivo tissue.
We examined several brain structures that are either
implicated in the pathogenesis of depression (i.e., the
prefrontal cortex, frontal cortex, and hippocampus)
(Holmes 2008) or linked to anhedonia (i.e., the striatal
areas) (Robinson et al. 2012) and are sites of biochemical
and morphological changes in depressed patients (Holmes
2008). Additionally, the cerebellum has been recently
identified as an area that receives negative functional
connectivity from the hippocampus in depressed subjects
(Cao et al. 2012). Our results suggest that chronic treatment
with antidepressants results in higher levels of AEA in the
hippocampus and dorsal striatum along with increased
levels of 2-AG in the dorsal striatum. These changes were
Fig. 4 2-AG levels in rat brain structures following chronic drug/
compound administration and 10-day washout period. 2-AG 2-Arach-
idonoylglycerol, IMI(15) imipramine hydrochloride (15 mg/kg),
ESC(10) escitalopram oxalate, TIA(10) tianeptine sodium,
NAC(100) N-acetylcysteine, URB597(0.3) cyclohexylcarbamic acid
3-carbamoylbiphenyl-3-yl ester, PFCTX prefrontal cortex, FCTX
frontal cortex, HIP hippocampus, DSTR dorsal striatum, NAc nucleus
accumbens, CER cerebellum. All data are expressed as the mean ±
SEM. N = 8 rats/group. *p \ 0.05; **p \ 0.01; ***p \ 0.001 versus
corresponding vehicle
198 Neurotox Res (2014) 26:190–206
123
even maintained after a 10-day drug-free period that fol-
lowed repeated treatment with ESC and TIA. This is the
first study to report alterations in the levels of eCBs and
NAEs in the brain after the administration of clinically
approved antidepressant drugs (IMI, ESC, and TIA) or
drugs with antidepressant-like activity (NAC and
URB597).
Some changes in eCBs/NAEs levels could even be
observed only 24 h after a single dose the tested drugs. For
example, a single dose of either IMI or NAC evoked a
significant increase in AEA levels in the hippocampus or
dorsal striatum, respectively. Additionally, a single dose of
IMI or URB597 increased the levels of 2-AG in the frontal
cortex and dorsal striatum, respectively. In contrast, a
single dose of either IMI or NAC decreased 2-AG levels in
the cerebellum, while ESC and NAC have a similar effect
on cortical structures. Administering a single dose of TIA
or URB597 resulted in a significant decrease in NAE levels
in the hippocampus (PEA and PEA/OEA, respectively),
while a single dose of IMI had the opposite effect in this
region. Additionally, NAC decreased NAE (OEA) levels in
the nucleus accumbens, and ESC decreased NAE levels
(both PEA/OEA) in both the frontal cortex and the
cerebellum. These changes occurred even though the drugs
were rapidly eliminated and both eCBs and NAEs were
rapidly degraded. These results imply that acute drug
administration can provoke rapid adaptive changes that
begin only 24 h after a single dose. Interestingly, these
changes were all maintained after chronic administration of
these drugs over the course of 14 days with the exception
of the increase in hippocampal NAE levels that was
observed after a single dose of IMI. Finally, the adaptive
changes in the frontal cortex and cerebellum that followed
ESC treatment were maintained even after a 10-day ESC-
free period.
A potent rise in the levels of eCBs, AEA and 2-AG, was
observed in the rat dorsal striatum 24 h after the chronic
administration of all tested drugs. In the present paper we
also report that striatal eCB levels also increase in response
to repeated URB597 treatment. Additionally, withdrawal
of this drug for 24 h initiates adaptive changes within the
eCB system, which may be associated with the antide-
pressant-like activity of this FAAH inhibitor. Injecting
URB597 2 h before decapitation induced a potent increase
in the levels of AEA, PEA, and OEA in multiple brain
structures, possibly because it acts in time-dependent
Fig. 5 PEA levels in rat brain structures following acute and chronic
drug/compound administration. PEA Palmitoylethanolamide, IMI(15)
imipramine hydrochloride (15 mg/kg), ESC(10) escitalopram oxalate,
TIA(10) tianeptine sodium, NAC(100) N-acetylcysteine, URB597(0.3)
cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester, PFCTX
prefrontal cortex, FCTX frontal cortex, HIP hippocampus, DSTR
dorsal striatum, NAc nucleus accumbens, CER cerebellum. All data
are expressed as the mean ± SEM. N = 8 rats/group. *p \ 0.05;
**p \ 0.01; ***p \ 0.001 versus corresponding vehicle
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manner in which an increase of AEA levels lasts between
30 min and 2 h while PEA/OEA levels are maintained up
to 6 h (the present paper; Kathuria et al. 2003; Fegley et al.
2005; Piomelli et al. 2006). A previously study by Borto-
lato et al. (2007) has suggested that treatment for 5 weeks
with URB597 also enhances striatal AEA levels but does
not affect 2-AG levels in control rats or rats exposed to
chronic mild stress (CMS) (Bortolato et al. 2007). Our
findings suggest that the antidepressant drugs may exert
their therapeutic effects by normalizing eCB levels within
the striatum that have been disturbed during depression. In
support of this hypothesis, one cortical symptom of
depression is anhedonia, which has been linked to the
abnormal functioning of CB1 receptors in the ventral stri-
atum in rats (Hill et al. 2008b). These same alterations have
also been observed in anhedonia-related animal models of
depression, including chronic unpredictable stress (CUS)
and CMS (Hill et al. 2008b; Reich et al. 2013a, b; Segev
et al. 2013). Anhedonia is associated with a weakening of
the eCB signal in the ventral striatum and with reduced
local levels of AEA (Hill et al. 2008b). In this study we
detected changes in eCB levels in the dorsal striatum in
response to treatment with IMI, ESC, TIA, NAC, or
URB597. In contrast, eCB levels only changed in the
ventral region (the nucleus accumbens) after chronic
administration of NAC. It is still unclear whether changes
in eCB levels directly altered the levels of CB receptors or
enzymes, although one previous report indicated that an
increase in the density of CB1 receptors was observed in
the ventral striatum after reduced levels of AEA (via
increased FAAH activity) occurred in alcoholic suicide
victims (Vinod et al. 2010). In this paper, we also report
that striatal NAE levels increased after chronic treatment
with IMI and NAC. One possibility is that increased PEA
and OEA levels could strengthen the effect of AEA on CB
or vanilloid (TRPV1) receptors (i.e., the ‘‘entourage
effect’’), which could in turn potentiate the effect of eCBs
(De Petrocellis et al. 2001; Smart et al. 2002). Another
possibility is that NAEs may increase hippocampal cera-
mide levels, stabilize mitochondrial function and inhibit
the degradation of AEA, which could together have a
neuroprotective effect (Skaper et al. 1996; Nagayama et al.
1999). Our findings add to the previous scientific literature
regarding the effects of antidepressants on the eCB system
with one important contradiction. IMI was previously
found to lower the expression of CB1 receptors in the
Fig. 6 PEA levels in rat brain structures following chronic drug/
compound administration and 10-day washout period. PEA Palmitoy-
lethanolamide, IMI(15) imipramine hydrochloride (15 mg/kg), ESC(10)
escitalopram oxalate, TIA(10) tianeptine sodium, NAC(100) N-acetyl-
cysteine, URB597(0.3) cyclohexylcarbamic acid 3-carbamoylbiphenyl-
3-yl ester, PFCTX prefrontal cortex, FCTX frontal cortex, HIP
hippocampus, DSTR dorsal striatum, NAc nucleus accumbens, CER
cerebellum. All data are expressed as the mean ± SEM. N = 8 rats/
group. *p \ 0.05; **p \ 0.01; ***p \ 0.001 versus corresponding
vehicle
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ventral striatum (Hill et al. 2008b) but had no effect on
eCB levels in the rat brain (Bortolato et al. 2007; Hill et al.
2008b). The rise in eCB levels that we observed in this
study may be result of either differing IMI dosages (Hill
et al. used a lower dose), duration of treatment (Bortolato
et al. used a 5-week procedure), and/or the sensitivity of the
different methods used to measure eCB levels (isotope-
dilution liquid chromatography|[minus]|mass spectrometry
vs. LC–MS/MS).
As in the striatum, chronic treatment with antidepressant
drugs also enhances AEA levels in the hippocampus. Pre-
vious studies have demonstrated that eCB signaling
decreases in the hippocampus in an animal model of
depression (Hill et al. 2005). Additionally, a reduction in
hippocampal size has been observed during depression
(McLaughlin and Gobbi 2012), and the local administra-
tion of a CB1 receptor agonist in the dentate gyrus has
elicited an antidepressant-like response (McLaughlin et al.
2007). The eCB system, particularly AEA/CB1 receptor
signaling, is an important mediator of neurogenesis within
the hippocampus. The activation of these receptors directs
neural precursor cells into a mitogenic state via the acti-
vation of the phosphatidylinositol-3 kinase (PI3K)/Akt
pathway, which promotes cannabinoid-induced prolifera-
tion (Galve-Roperh et al. 2002; Ozaita et al. 2007).
Increased hippocampal levels of AEA can both reduce
excitotoxic damage within the hippocampus and induce
protective mechanisms in hippocampal neurons, which
may be linked to the influence of the eCB system on the
hypothalamic–pituitary–adrenal (HPA) axis (Marsicano
et al. 2003). Thus, rats subjected to chronic stress or
repeated administration of corticosteroids experience a
drop in both the concentration of eCBs and expression of
CB1 receptors in the hippocampus (Hill et al. 2005, 2008a,
2009). Furthermore, activation of the stress axis, which
results from a reduction in the inhibitory effect of hippo-
campal neurons on limbic structures, has been associated
with decreased activation of the eCB system in local
GABAergic neurons (Hu et al. 2011). At sites of GAB-
Aergic inputs in the hippocampus (CA1 region), the acti-
vation of CB1 receptors induces various mechanisms of
synaptic plasticity, including depolarization-induced sup-
pression of inhibition (DSI) and long-term depression of
inhibitory synapses (I-LTD) (Lovinger 2008). Addition-
ally, previous studies have suggested that hippocampal
levels of 2-AG are elevated 24 h or 10 days after chronic
Fig. 7 OEA levels in rat brain structures following acute and chronic
drug/compound administration. OEA Oleoylethanolamide, IMI(15)
imipramine hydrochloride (15 mg/kg), ESC(10) escitalopram oxalate,
TIA(10) tianeptine sodium, NAC(100) N-acetylcysteine, URB597(0.3)
cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester, PFCTX
prefrontal cortex, FCTX frontal cortex, HIP hippocampus, DSTR
dorsal striatum, NAc nucleus accumbens, CER cerebellum. All data
are expressed as the mean ± SEM. N = 8 rats/group. *p \ 0.05;
**p \ 0.01; ***p \ 0.001 versus corresponding vehicle
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administration of ESC. A recent study found that inhibiting
monoacylglycerol lipase (MAGL), which is an enzyme
involved in 2-AG degradation, produces antidepressant-
like effects through the enhancement of eCB signaling
through the mammalian target of rapamycin (mTOR)
pathway in the hippocampus (Zhong et al. 2014), which
suggests a possible involvement of increased 2-AG levels
in the antidepressant mechanism of ESC. In addition to
eCBs, NAE levels also change in the rat hippocampus. IMI
elicits an increase in both PEA and OEA, while ESC
increases PEA levels and NAC increases OEA levels. In
contrast, TIA decrease PEA levels, and URB597 decreases
both PEA and OEA levels. Along with eCBs, these NAEs
may also participate in controlling synaptic plasticity via
Kv4.3 potassium channels in hippocampal interneurons
along with ascending pyramidal and GABAergic cortical
neurons (Burkhalter et al. 2006; Bourdeau et al. 2007). As
reported previously, chronic treatment with desipramine (a
NA and 5-HT reuptake inhibitor) or tranylcypromine (a
monoamine oxidase inhibitor) enhances the expression of
CB1 receptors in the hippocampus, although only tranyl-
cypromine decreased AEA levels in the hippocampus (Hill
et al. 2006, 2008c). These studies suggest that the
regulation of CB1 receptors in specific brain structures after
antidepressant treatment might result from adaptive chan-
ges and could vary depending on the levels of both
receptors and ligands. In particular, Bortolato et al. sug-
gested that chronic treatment with URB597 did not
increase hippocampal AEA levels; in fact, prolonged
(5 week) exposure may instead down-regulate AEA in the
hippocampus (Bortolato et al. 2007). However, this effect
is still poorly understood.
As reported, there were significant alterations in eCB
and NAE levels the rat prefrontal cortex, which participates
in a variety of functions including learning and memory.
For example, increased activation of the eCB system has
been observed to strengthen memory (Lafourcade et al.
2007). Reinforcing emotional memories of aversive stimuli
can increase levels of eCBs in the prefrontal cortex, which
may induce emotional discomfort during depression. In
fact, elevated levels of eCBs and CB1 receptors have been
observed in the dorsolateral prefrontal cortex of alcoholic
suicide victims (Vinod et al. 2005). Here, we observed a
decrease in the concentration of 2-AG after the chronic
administration of ESC and NAC, which may be a potential
mechanism for the antidepressant-like activity of these
Fig. 8 OEA levels in rat brain structures following chronic drug/
compound administration and 10-day washout period. OEA Oleoy-
lethanolamide, IMI(15) imipramine hydrochloride (15 mg/kg),
ESC(10) escitalopram oxalate, TIA(10) tianeptine sodium,
NAC(100) N-acetylcysteine, URB597(0.3) cyclohexylcarbamic acid
3-carbamoylbiphenyl-3-yl ester, PFCTX prefrontal cortex, FCTX
frontal cortex, HIP hippocampus, DSTR dorsal striatum, NAc nucleus
accumbens, CER cerebellum. All data are expressed as the mean ±
SEM. N = 8 rats/group. *p \ 0.05; **p \ 0.01; ***p \ 0.001 versus
corresponding vehicle
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drugs in the prefrontal cortex. In contrast, Hill et al.
(2008c) indicated that tranylcypromine increases the level
of 2-AG and enhances the density of CB1 receptors in the
prefrontal cortex (Hill et al. 2008c). However, other reports
have demonstrated that CB1 receptors in the prefrontal
cortex can participate in the antidepressant actions of CB1
receptor agonists and that increases in local AEA signaling
can modulate stress coping behaviors via the activation of
serotonergic neurons in the raphe nucleus (Bambico et al.
2007; McLaughlin et al. 2012). Additionally, chronically
administering fluoxetine can fully reverse the enhanced
CB1-receptor signaling seen in bulbectomized rats
(Rodriguez-Gaztelumendi et al. 2009) and can also mod-
ulate the function (but not the density) of CB1 receptors in
the prefrontal cortex (Mato et al. 2010). In this study, we
also noted an increase in PEA levels in the prefrontal
cortex after chronic treatment with IMI, NAC and the
FAAH inhibitor. Because PEA administration (5–40 mg/
kg) by itself can reduce a mouse’s immobility time in the
TST and FST, which is a behavioral indication of antide-
pressant-like activity (Yu et al. 2011), the increased PEA
levels might contribute to the antidepressant-like effect
these drugs. In contrast, a decrease in NAE levels was
observed in the prefrontal cortex after TIA chronic treat-
ment, and reduced PEA levels were maintained after the
TIA-free period. This TIA-specific effect might be related
to the adaptive changes associated with NAE depletion or
to changes in eCB receptors, enzymes or transporters.
Anti-depressant drugs had different effects in other brain
regions. In the frontal cortex, chronic administration of
NAC increased AEA levels, while 2-AG levels increased
after IMI, TIA and NAC treatment but decreased after ESC
treatment. Changes in cortical eCB levels has not yet been
established in postmortem or ex vivo studies, although it
has been observed that CB1 receptor density decreases in
mood disorders (Koethe et al. 2007) and increases in both
depressed suicide victims and animal models of depression
(Hungund et al. 2004; Choi et al. 2012). Long-term flu-
oxetine treatment in obese Zucker rats reduces these ele-
vated CB1 receptor levels in the frontal cortex, which
suggests that the eCB system is involved in mediating the
effects of fluoxetine via the influence of 5-HT enhancement
on CB1 receptor levels (Zarate et al. 2008). NAE levels in
the frontal cortex also fell both 24 h and 10 days after ESC
treatment was withdrawn, which many contribute to the
antidepressant effect of ESC via the dampening TRPV1-
mediated signaling. In support of this hypothesis, previous
studies have suggested that the loss of TRPV1 results in
antidepressant, anxiolytic, abnormal social and reduced
memorial behaviors (You et al. 2012). However, the exact
mechanism remains unclear.
In contrast to chronic IMI treatment, cortical NAE levels
were reduced after treatment with TIA and ESC, which
most likely stems from their differential effects on NA and
5-HT signaling. One possibility is that the increase in NAE
levels observed after IMI treatment might reduce NA
release and normalize the increased synaptic availability
that is induced by IMI treatment; however, future studies
are needed to test this hypothesis.
We also examined the effect of chronic antidepressant
treatment on the rat cerebellum, which has recently been
implicated in the pathogenesis of depression, specifically
disturbances in cerebellar–hippocampal projections (Cao
et al. 2012). In this study, we report drug-dependent
changes in cerebellar levels of both eCBs (AEA increases
after the chronic administration of URB597, while 2-AG
decreases after the acute or chronic administration of IMI
and NAC and the chronic administration of ESC) and
NAEs (PEA increases after the chronic administration of
URB597 but PEA and OEA decrease after chronic treat-
ment with IMI or ESC). eCBs act as retrograde messengers
in the cerebellum, which allows eCB signals to be trans-
mitted through depolarization of Purkinje cells or local
interneurons and permits signal transmission over long
distances (Kreitzer et al. 2002). Suarez et al. (2008)
detected the presence of components of the eCB system in
cerebellar tissue, which suggests that eCBs might partici-
pate in the development of cerebellar synaptic plasticity
[either long term depression (LTD) or long term potentia-
tion (LTP)] (Suarez et al. 2008). Lowered levels of 2-AG
after antidepressant treatment (IMI, ESC and NAC) might
regulate the plasticity of synapses being made onto Pur-
kinje cells and could play a key role in normalizing LTD in
the cerebellar cortex (Safo et al. 2006; Carey et al. 2011;
Zhong et al. 2011).
Interestingly, the effects of antidepressants on the eCB
system seem to be short-lived. After a 10-day washout
period, eCB concentrations returned to control (vehicle)
levels except in animals treated with ESC and TIA. The
chronic administration of ESC altered eCB levels in mul-
tiple brain regions (e.g., frontal cortex, hippocampus,
dorsal striatum, and cerebellum), and these effects were
maintained even after the drug-free period. It is still unclear
whether adaptive changes existed within the eCB system
(e.g., changes in enzyme activity, receptor density, eCB
transport, etc.) after 14 days of ESC treatment. However,
the drug-free period did increase the levels of NAEs in the
nucleus accumbens, which was not observed after the acute
or chronic administration of TIA. TIA possesses a unique
mechanism of antidepressive action and has a specific
pharmacokinetic profile. In fact, recent studies have
established that unlike other antidepressants, TIA enhances
serotonin reuptake and is not primarily metabolized by the
hepatic cytochrome P450 system. TIA also stimulates DA
release in the nucleus accumbens and acts as a glutama-
tergic modulator, which influences central neuronal
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remodeling and restoration of neuronal plasticity (Inver-
nizzi et al. 1992; Vadachkoria et al. 2009). However,
understanding the relevance of these multi-targeted inter-
actions will require further study.
Conclusion
As demonstrated here, changes in eCB and NAE levels in
various rat brain structures indicate that these lipids may play
a significant role in the mechanism of the anti-depressant
drugs IMI, ESC, TIA, NAC, and URB597. Further studies
involving selective antagonists of CB1 and CB2 receptors
will be necessary to accurately determine the role of the eCB
system in the mechanism of action of these drugs. Together,
these studies will help determine whether the stimulation of a
specific cannabinoid receptor is necessary or if increased
eCB action on other targets (e.g., TPRV1 or PPARa) is
instead responsible. Further studies are also needed to
explore whether the eCB system could function as a ‘‘central
player’’ in the pathogenesis of depression through its effects
on cellular processes (levels of neurotransmitters, processes
of neurogenesis, HPA axis, etc.). Understanding the role of
the eCB system in the mechanism of action of clinically
effective antidepressants may implicate eCBs as a target for
drug design and discovery.
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